Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 4, 2015, Pages 1109-1117

  Indra, Tomáš ^a   Holaj, Robert ^a   Štrauch, Branislav ^a   Rosa, Ján ^a   Petrák, Ondej ^a   Šomlóová, Zuzana ^a   Widimský, Jií ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adrenalectomy; Echocardiography; Hypertension; Left ventricle hypertrophy; Primary aldosteronism

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; POTASSIUM; SPIRONOLACTONE; VERAPAMIL; ANTIHYPERTENSIVE AGENT;

ADENOMA; ADRENALECTOMY; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE WALL; HUMAN; HYPERTENSION; HYPOKALEMIA; MALE; PRIMARY HYPERALDOSTERONISM; REMISSION; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HYPERALDOSTERONISM; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; TIME FACTOR;

ADRENALECTOMY; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PREVALENCE; SPIRONOLACTONE; TIME FACTORS;

EID: 84952921072     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320314549220     Document Type: Article

References (43)

1. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300.
2. Štrauch B, Zelinka T, Hampf M, et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17: 349-352.
3. Hiramatsu K, Yamada T, Yukimura Y,. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity: Results in hypertensive patients. Arch Intern Med 1981; 141: 1589-1593.
4. Rossi G, Boscaro M, Ronconi V, et al. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005; 16: 104-107.
5. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85.
6. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248.
7. Steichen O, Amar L, Plouin PF,. Cardiovascular complications in patients with primary hyperaldosteronism: A controlled cross-sectional study: PP.18.178. J Hypertens 2010; 28: e302-e303.
8. Rizzoni D, Paiardi S, Rodella L, et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2638-2642.
9. Rossi GP, Di Bello V, Ganzaroli C, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002; 40: 23-27.
10. Schmidt BM, Schmieder RE,. Aldosterone-induced cardiac damage: Focus on blood pressure independent effects. Am J Hypertens 2003; 16: 80-86.
11. Robert V, Van Thiem N, Cheav SL, et al. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994; 24: 30-36.
12. Štrauch B, Petrák O, Wichterle D, et al. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006; 19: 909-914.
13. Holaj R, Zelinka T, Wichterle D, et al. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25: 1451-1457.
14. Muiesan ML, Salvetti M, Paini A, et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529-534.
15. Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039-1045.
16. Matsumura K, Fujii K, Oniki H, et al. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006; 19: 13-18.
17. Goldkorn R, Yurenev A, Blumenfeld J, et al. Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism and essential hypertension. Am J Hypertens 2002; 15: 340-345.
18. Yoshihara F, Nishikimi T, Yoshitomi Y, et al. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension. Am J Hypertens 1996; 9: 523-528.
19. Indra T, Holaj R, Zelinka T, et al. Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. J Renin Angiotensin Aldosterone Syst 2012; 13: 426-434.
20. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997; 95: 1471-1478.
21. Yoshitomi Y, Nishikimi T, Abe H, et al. Comparison of changes in cardiac structure after treatment in secondary hypertension. Hypertension 1996; 27 (3 Pt 1): 319-323.
22. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219.
23. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281.
24. Holland O, Brown H, Kuhnert L, et al. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6: 717-723.
25. Giacchetti G, Ronconi V, Lucarelli G, et al. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: Need for a standardized protocol. J Hypertens 2006; 24: 737-745.
26. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
27. Gosse P, Jullien V, Jarnier P, et al. Echocardiographic definition of left ventricular hypertrophy in the hypertensive: Which method of indexation of left ventricular mass? J Hum Hypertens 1999; 13: 505-509.
28. Catena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918.
29. Blumenfeld JD, Sealey JE, Schlussel Y, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877-885.
30. Rossi GP, Bolognesi M, Rizzoni D, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008; 51: 1366-1371.
31. Weber K, Brilla C,. Pathological hypertrophy and cardiac intersticium fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
32. Makhanova N, Hagaman J, Kim HS, et al. Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension 2008; 51: 134-140.
33. Funder J,. Mineralocorticoids and cardiac fibrosis: The decade in review. Clin Exp Pharmacol Physiol 2001; 28: 1002-1006.
34. Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62: 62-69.
35. Grandi AM, Solbiati F, Laurita E, et al. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: A randomized, controlled pilot study. Am J Hypertens 2008; 21: 231-237.
36. Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009; 120: 1380-1389.
37. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-537.
38. Reil JC, Hohl M, Selejan S, et al. Aldosterone promotes atrial fibrillation. Eur Heart J 2012; 33: 2098-2108.
39. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168: 1159-1164.
40. Gaddam K, Corros C, Pimenta E, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism. Hypertension 2010; 55: 1137-1142.
41. Funder JW,. Aldosterone and the cardiovascular system: Genomic and nongenomic effects. Endocrinology 2006; 147: 5564-5567.
42. Ori Y, Chagnac A, Korzets A, et al. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant 2013; 28: 1787-1793.
43. Strauch B, Petrak O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31: 2455-2461.